APAC IVD market to shrink by 2026 as demand for covid-19 testing cools further

Article tags In-vitro diagnosticsAsiaIVD Gateway

The Asia-Pacific (APAC) in-vitro diagnostics (IVD) market is expected to increase at an annual average of 4.4% from 2021 to 2026. The APAC market will continue to see key trends in hospital and patient care, government policies which will drive up overall diagnosis needs, and fuel fast growth for certain markets. Covid-19 has driven strong growth in the APAC IVD sector where revenues of IVD test reagents and instruments have surpassed their pre-pandemic size. 

However as demand for covid-19 testing cools further in 2023, Outside of China most IVD markets in APAC are expected to contract by 2026 as revenues recede from covid-related testing.

Despite the overall contraction of the APAC IVD market, there are growth opportunities in areas such as centralised diagnostics and point-of-care testing for infectious diseases outside of covid-19.

Key forecasts for 2021-2026

• China, Myanmar and Pakistan are the few IVD markets expected to sustain growth post-pandemic, while most APAC IVD markets are expected to shrink as countries scale back on covid-19 testing.
• Clinical sequencing is expected to be the fastest-growing major market segment.
• Centralised diagnostics (CEDx) is expected to make a full recovery and grow moderately. Immunoassays, which account for a large part of the CEDx segment revenue, continue to be integral to growth, with rising incidence of chronic and infectious diseases in APAC expected to drive increased testing in the area.
• Molecular diagnostics (MDx) is expected to grow strongly across the majority of test areas including virology and genomics, with solid patient volume growth and a growing demand for more accurate diagnostics. Countries that have invested heavily in MDx instruments in 2020 and 2021—including China, India and Vietnam—are expected to show strong growth in many MDx test segments.
• Point-of-care (POC) diagnostics market segment is expected to weaken overall as covid-19 testing winds down. Strong growing demand for POC testing for infectious disease areas outside of covid-19.
• Tissue diagnostics (TDx) is expected to grow in the forecast period, led by growing oncology incidence and test volume in the region, with therapeutic diagnostics in oncology expected to boost market development in advanced staining over the next few years.

Growing Your IVD Business in APAC

As the APAC IVD market continues to evolve, the region provides numerous opportunities for companies seeking market growth and expansion. 

Successful growth strategies must address each market’s distinct challenges. Through EIU Healthcare’s team of consultants and IVD Gateway – our proprietary data solution, we support your strategic and tactical business planning and provide answers on the what, where and how to gain market share. 

Thu, 09th Feb 2023 Article tags In-vitro diagnosticsAsiaIVD Gateway